Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
复制标题
DOI：
10.3346/jkms.2021.36.e115
复制
发表时间：
2021-05-03
影响因子：
4.5
通讯作者：
Kim SH
中科院分区：
文献类型：
--
作者：
Bae S;Lee YW;Lim SY;Lee JH;Lim JS;Lee S;Park S;Kim SK;Lim YJ;Kim EO;Jung J;Kwon HS;Kim TB;Kim SH
我们对韩国医护人员（HCWs）首次接种两种新型冠状病毒病（COVID-19）疫苗后的不良反应进行了前瞻性调查。韩国首尔一家三级转诊医院的医护人员在2021年3月5日至26日期间接种了黑猩猩腺病毒载体疫苗（ChAdOx1 nCoV-19）或基于mrna的疫苗（BNT162b2）。要求卫生保健员在接种疫苗后三天内通过流动自我报告问卷报告不良反应。在研究期间，共有7625名卫生保健工作者接受了第一剂ChAdOx1或BNT162b2疫苗。其中至少参加过一次调查的HCWs 5866例（占76.9%）（ChAdOx1, n = 5589例[95.3%];BNT162b2, n = 277例[4.7%]），其中77%为女性，年龄小于50岁的占86%。ChAdOx1组总不良反应率为93%，BNT162b2组总不良反应率为80% （P < 0.001）。在ChAdOx1组中，局部反应和全身反应均更为常见，而发热和疲劳等全身反应的差异更大。在ChAdOx1组中，不良反应的发生率在女性和低龄组中明显较高，而BNT162b2组的不良反应发生率在年龄上存在差异。在我们的前瞻性调查中，ChAdOx1组的疫苗相关不良反应比BNT162b2组更常见。女性和年轻年龄组更频繁地出现疫苗相关不良反应。
We performed a prospective survey on the adverse reactions following the first dose of two types of vaccines against coronavirus disease 2019 (COVID-19) in healthcare workers (HCWs) in South Korea. HCWs at a tertiary referral hospital in Seoul, South Korea, received a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) or an mRNA-based vaccine (BNT162b2) between March 5 and March 26, 2021. The HCWs were asked to report adverse reactions through a mobile self-report questionnaire for three days after vaccination. A total of 7,625 HCWs received the first dose of ChAdOx1 or BNT162b2 vaccine during the study period. Of them, 5,866 (76.9%) HCWs (ChAdOx1, n = 5,589 [95.3%]; BNT162b2, n = 277 [4.7%]) participated at least once in the survey, of whom 77% were female and 86% were younger than 50 years. The overall adverse reaction rate was 93% in the ChAdOx1 group and 80% in the BNT162b2 group (P < 0.001). Both local and systemic reactions were more commonly reported in the ChAdOx1 group, and the difference was larger in systemic reactions such as fever and fatigue. In the ChAdOx1 group, the incidence of adverse reactions was significantly higher in females and those in the younger age groups, while the BNT162b2 group showed such difference according to age. In our prospective survey, vaccine-associated adverse reactions were more commonly reported in the ChAdOx1 group than in the BNT162b2 group. Females and younger age groups experienced vaccine-associated adverse reactions more frequently.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1038/s41577-021-00526-x
发表时间：
2021-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Teijaro JR;Farber DL
通讯作者：
Farber DL
DOI：
10.1016/s0140-6736(20)32466-1
发表时间：
2021-12-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
Ramasamy MN;Minassian AM;Ewer KJ;Flaxman AL;Folegatti PM;Owens DR;Voysey M;Aley PK;Angus B;Babbage G;Belij-Rammerstorfer S;Berry L;Bibi S;Bittaye M;Cathie K;Chappell H;Charlton S;Cicconi P;Clutterbuck EA;Colin-Jones R;Dold C;Emary KRW;Fedosyuk S;Fuskova M;Gbesemete D;Green C;Hallis B;Hou MM;Jenkin D;Joe CCD;Kelly EJ;Kerridge S;Lawrie AM;Lelliott A;Lwin MN;Makinson R;Marchevsky NG;Mujadidi Y;Munro APS;Pacurar M;Plested E;Rand J;Rawlinson T;Rhead S;Robinson H;Ritchie AJ;Ross-Russell AL;Saich S;Singh N;Smith CC;Snape MD;Song R;Tarrant R;Themistocleous Y;Thomas KM;Villafana TL;Warren SC;Watson MEE;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Faust SN;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1001/jama.2021.0600
发表时间：
2021-02-23
期刊：
JAMA
影响因子：
--
作者：
Shimabukuro T;Nair N
通讯作者：
Nair N